bergenbio continu report promis data phase ii studi non-smal
cell lung cancer nsclc bemcentinib combin pembrolizumab
occas progress free surviv data final data
current trial due next six month result date
suffici compel compani alreadi start prepar randomis
phase ii trial programm bemcentinib begin detail phase ii
studi disclos expect compani run seri trial
variou nsclc set includ pembrolizumab aml rais
valuat bergenbio per share
data emphasis potenti bemcentinib pembrolizumab
bergenbio previous report promis overal respons rate orr data
stage phase ii studi pembrolizumab merck keytruda orr
patient axl tumour vs axl- tumour
consist bergenbio report median month
month patient axl axl- tumour respect histor
trial pembrolizumab nivolumab monotherapi low nsclc median
 month stage activ recruit extra patient trial
randomis phase ii studi initi bergenbio plan
randomis phase ii trial start detail disclos
compani like centr bemcentinib potenti second-lin
nsclc particular pembrolizumab aml/md studi
probabl includ pre-specifi analys patient stratifi use biomark
express confirm observ made current trial
enter clinic phase studi healthi volunt
antibodi due start decemb single-ascend
dose trial six patient per cohort trial expect complet
aim initi phase i/ii studi patient bergenbio
yet indic indic develop inhibit
signal like bemcentinib could develop oncolog fibrosi
valuat increas rais
valuat bergenbio
follow result promis data nsclc termin
develop programm triple-neg breast cancer also revis
estim take account tight cost control expand
clinic trial programm randomis phase ii trial bergenbio
cash posit suffici oper
share issu
bergenbio clinical-stag
biopharmaceut compani base
bergen norway oxford uk
develop innov therapi
aggress cancer way
inhibit signal pathway
bemcentinib multipl phase ii
valuat financi
valuat bergenbio
increas
revis valuat take account compani progress
clinic trial increas valuat bergenbio
detail exhibit main chang model
remov tnbc increas probabl success
nsclc pembrolizumab docetaxel due promis data
present sinc meet june
exhibit rnpv-base valuat bergenbio
success
nsclc
nsclc
nsclc
base
indic
pembrolizumab
likelihood receipt
revenu payabl rigel
start
triniti delta note valuat assum out-licens valu indic includ current
expens associ current clinic trial hnscc head neck squamou cell carcinoma chl classic hodgkin lymphoma msi-h
still consid reason includ bemcentinib broader potenti
immuno-oncolog therapi given promis data data nsclc howev
note bergenbio share current trade discount
core valuat also place valu antibodi
addit data current clinic trial present next six
month variou confer probabl includ
decemb march april may june
new data could act share price catalyst eagerli await result
overal surviv data first stage phase ii studi nsclc
pembrolizumab result trial second stage
hope confirm find first stage data report
also amend estim summaris exhibit chang
reflect compani tight cost control lower spend due
termin tnbc studi short-term anticip
invest increas significantli bergenbio roll
randomis phase ii programm refin estim
beyond bergenbio announc develop programm
exhibit summari chang estim
exhibit summari financi
triniti deltayear-end dec good oper profit financ tax incom ep share marginn/an/an/an/an/aebitda marginn/an/an/an/an/abal sheetcurr cash current plant portfolio non-curr current non-curr statementsoper cash work cash tangibl invest portfolio invest cash cash financ cash increas rate start end cash end bergenbio
triniti delta research limit tdrl firm refer number trade triniti delta appoint repres
equiti develop limit ed content report prepar sole respons tdrl
review independ verifi ed authoris regul fca whose refer number
ed act tdrl person respons provid protect provid client tdrl
advis person connect content report except extent requir applic law
includ rule fca owe duti care person relianc may place ed advic
recommend respect content report extent may applic law ed make
represent warranti person read report regard inform contain
prepar report tdrl use public avail sourc taken reason effort ensur fact state
herein clear fair mislead make guarante warranti accuraci complet inform
opinion contain herein provid updat fresh inform becom avail opinion chang
person relev person section section financi servic market act unit
kingdom act reli document content research client compani produc tdrl normal
commiss paid compani issuer financ research deem independ
defin fca object author state opinion report consid market
commun purpos fca rule prepar accord legal requir design promot
independ invest research subject prohibit deal ahead dissemin invest research
tdrl hold posit compani mention report although director employe consult tdrl
may hold posit compani mention tdrl impos restrict person deal tdrl might also provid servic
compani mention solicit busi
report provid relev person provid background inform subject matter note document
constitut form part constru offer sale purchas solicit invit
make offer buy sell secur may rise fall valu shall part form basi reli
connect contract commit whatsoev inform provid intend
manner whatsoev constru personalis advic self-certif investor complet free charg
www fisma org tdrl affili offic director employe ed liabl loss damag aris use
document maximum extent law permit
inform avail websit www trinitydelta org
